The Immunologic Sciences Special Emphasis Panel ZRG1 IMM-12 reviews applications from the small business community in the areas of immune responses and vaccines to non-HIV microbial infections for the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer Research (STTR) Programs.

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates


  • Immune responses and vaccines against microorganisms (except HIV) including investigation of available antibodies and therapeutics directly targeting the immune response against those microorganisms.
  • Antigen and epitope identification, selection and immunogenecity; use of adjuvants; vectors and chimeric carriers; vaccine formulation.
  • Vaccine production: production methodologies, process development/optimization/scale-up, GMP production and manufacturing of clinical material.
  • Vaccine and adjuvant delivery systems: bacterial and viral vectors, chimeric vaccine carriers, liposomes, nanoparticles.
  • Use of animal models to study vaccines and available immunotherapeutics.

There are shared interests with Non-HIV Anti-Infective Therapeutics Special Emphasis Panel [IDM (10)] and Microbial Diagnostics and Detection of Infectious Agents, Food and Waterborne Pathogens, and Methods in Microbial Sterilization, Disinfection and Bioremediation Special Emphasis Panel (IDM (12)) in the development of immunoassays for infectious agents and the development of agents to combat microbial-induced diseases. Applications directly targeting the microorganisms may be reviewed in IDM-10 or IDM-12, whereas studies evaluating the immune system or immune responses to infectious agents may be reviewed in IMM-12.

There are shared interests with AIDS and Related Research HIV/AIDS Small Business Special Emphasis Panel [AARR (10)] in the design of viral vaccines. Applications involving HIV vaccine research may be reviewed in AARR-10. Applications involving vaccines for other non-HIV viral infections may be reviewed in IMM-12.

There are shared interests with Biomaterials, Delivery, and Nanotechnology Special Emphasis Panel [BST (10)] in biomaterials, nanotechnology, gene, protein and drug delivery technologies. Applications involving drug formulation, manufacturing, biocompatibility and toxicity investigations may be reviewed in BST-10. Applications studying immune responses and anti-microbial vaccines may be reviewed in IMM-12.

There are shared interests with Drug Discovery and Development Special Emphasis Panel [BCMB (10)] in drug discovery and development. Applications concerning medicinal chemistry, small molecule drug discovery and development, pharmaceutical chemistry, protein engineering and protein chemistry for drug discovery, may be reviewed in BCMB-10. Applications studying antimicrobial vaccines and available immune-interfering peptides and proteins may be reviewed in IMM-12.

There are shared interests with Bioanalytical Chemistry, Biophysics, and Assay Development Special Emphasis Panel [IMST (10)] on antibody development. Disease-agnostic assay development, biochemistry and protein engineering including creating synthetic antibodies may be reviewed in IMST (10). Use of available antibodies as therapeutic vaccines against infections may be reviewed in IMM-12.

There are shared interests with Innovative Immunology Special Emphasis Panel [IMM (10)] in the development of vaccines. Applications involving the use of vaccines against cancer, autoimmune disease, allergy, asthma, or to aid in transplantation may be reviewed in IMM-10. Applications focused on the investigation of immune responses, therapeutics or novel vaccines against non-HIV infectious agents may be reviewed in IMM-12.